Gilead Sciences (GILD Quick QuoteGILD - Free Report) reported $6.95 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 5.4%. EPS of $2.01 for the same period compares to $1.34 a year ago.

The reported revenue represents a surprise of +4.71% over the Zacks Consensus Estimate of $6.64 billion. With the consensus EPS estimate being $1.61, the EPS surprise was +24.84%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Sales- Other Product- Other- U.S.

  $98 million compared to the $37.97 million average estimate based on three analysts. The reported number represents a change of +276.9% year over year.

• Product Sales- Vemlidy- U.S

  : $117 million versus the three-analyst average estimate of $95.72 million. The reported number represents a year-over-year change of +21.9%.

• Product Sales- Total HIV- US

  : $3.82 billion versus the three-analyst average estimate of $3.92 billion. The reported number represents a year-over-year change of +1.1%.

• Product Sales- Descovy- U.S

  : $434 million versus the three-analyst average estimate of $456.12 million. The reported number represents a year-over-year change of -5.7%.

• Product Sales- Biktarvy- Total

  : $3.23 billion versus the eight-analyst average estimate of $3.19 billion. The reported number represents a year-over-year change of +8.5%.

• Product Sales- Tecartus- Total

  : $107 million compared to the $105.31 million average estimate based on eight analysts. The reported number represents a change of +21.6% year over year.

• Product Sales- Yescarta- Total

  : $414 million versus the eight-analyst average estimate of $398.21 million. The reported number represents a year-over-year change of +9%.

• Product Sales- Trodelvy- Total

  : $320 million versus the eight-analyst average estimate of $344.28 million. The reported number represents a year-over-year change of +23.1%.

• Product Sales- HIV- Total

  : $4.75 billion compared to the $4.71 billion average estimate based on eight analysts. The reported number represents a change of +2.6% year over year.

• Revenues- Royalty contract and other revenues

  : $41 million versus $44.17 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +17.1% change.

• Revenues- Product sales

  : $6.91 billion compared to the $6.60 billion average estimate based on eight analysts. The reported number represents a change of +5.3% year over year.

• Product Sales- Total Veklury

  : $214 million versus the seven-analyst average estimate of $197.96 million. The reported number represents a year-over-year change of -16.4%.

View all Key Company Metrics for Gilead here>>>

Shares of Gilead have returned +7.6% over the past month versus the Zacks S&P 500 composite's -6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.